Hayley Crawford, PhD, and Carl Marci, MD, discuss how their specific industries have developed new innovations in response to the COVID-19 pandemic.

The disease area that has received the most attention, time, and financial support during the last two years has been COVID-19. There has been tremendous emphasis on addressing the new challenges presented during this global pandemic, including rapid vaccine development, effective patient treatments, supplying reliable testing methods, and providing equitable healthcare access for diverse populations. Participate to learn about innovations that have been recently developed for the fight against SARS-CoV-2.

Dr. Hayley Crawford describes Integral Molecular’s catalog of 70+ SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotypedviruses) that enable researchers to rapidly test neutralization by antibodies and sera in a safe BSL-2 environment. The presentation covers Integral Molecular’s RVP offerings that include Omicron subvariants BA.1 and BA.2,and neutralizing antibody controls. Dr. Crawford also describes additional research solutions from Integral Molecular such as epitope mapping and antibody specificity profiling and how these tools together meet the most recent FDA recommendations for variant testing of vaccines and therapeutic antibodies.

Dr. Carl Marci explores the pandemic from a different viewpoint. As has becoming increasingly clear, the effects of isolation at various stages of the COVID-19 pandemic have resulted in increased stress and anxiety in numerous populations. Using real-world data, Dr. Marci explains how real-world trends and diagnoses rates of anxiety and depression can be used to understand mental health before and after the beginning of the pandemic. Dr. Marci also highlights how real-world data can be used to understand mental health trends and patient outcomes.

Key Topics Include:

  • The use of SARS-CoV-2 RVPs to measure neutralization and how they compare with live virus
  • How tools like RVPs can be used to accelerate vaccine and antibody development in accordance with FDA guidance
  • Learn how real-world data can be used for understanding mental health trends during the pandemic
  • Explore the ways diagnostic codes and patient reported outcomes can be used for understanding patient journeys
  • Discuss use cases for real-world data in conditions such as anxiety and depression
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.


To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.


Research Scientist
Integral Molecular

Hayley Crawford is the Virology Project Leader at Integral Molecular and manages the company’s extensive Reporter Virus Particle (RVP) portfolio. She spearheads all aspects of the SARS-CoV-2 RVP product cycle—from product development through manufacturing and quality control—for current and emerging strains. Prior to joining Integral Molecular, Dr. Crawford was a postdoctoral researcher at Oxford University, where she worked on designing HIV vaccines using CD8+ T cell epitope constructs. She obtained her PhD from Oxford University and has over a decade of experience in virology and immunology.

Chief Psychiatrist and Managing Director
Mental Health and Neuroscience

Dr. Carl Marci is the Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1.

Production Partner

Integral Molecular

Integral Molecular is the industry leader in developing and applying innovative technologies that advance therapeutic discovery against difficult protein targets.


With specialization in chronic conditions, OM1 leverages its extensive, specialty clinical networks and an artificial intelligence (AI) platform to offer enriched health care datasets, research analytics, data modeling, decision support, and retrospective and prospective clinical studies.

Additional Content From OM1

Additional Content From Scientist.com

Additional Content From HealthEconomics.Com

Related Content

Integrating Patient Engagement and Trainee Development in Pre-Clinical Research

Integrating Patient Engagement and Trainee Development in Pre-Clinical Research

Christopher Perry, PhD discusses how his laboratory aims to discover mechanisms by which metabolic dysfunction causes muscle weakness and apply these findings to develop new therapies for muscle disorders. Homira Osman, PhD provides a particular focus on leveraging scientific findings for practice and policy and linking trainees with patient communities.